[go: up one dir, main page]

PE20240584A1 - Agonistas del receptor de glp-1 y usos de los mismos - Google Patents

Agonistas del receptor de glp-1 y usos de los mismos

Info

Publication number
PE20240584A1
PE20240584A1 PE2023003553A PE2023003553A PE20240584A1 PE 20240584 A1 PE20240584 A1 PE 20240584A1 PE 2023003553 A PE2023003553 A PE 2023003553A PE 2023003553 A PE2023003553 A PE 2023003553A PE 20240584 A1 PE20240584 A1 PE 20240584A1
Authority
PE
Peru
Prior art keywords
alkyl
compound
independently
glp
crz
Prior art date
Application number
PE2023003553A
Other languages
English (en)
Inventor
Gary Erik Aspnes
Scott W Bagley
John M Curto
David James Edmonds
Mark E Flanagan
Kentaro Futatsugi
David A Griffith
Kim Huard
Yajing Lian
Chris Limberakis
Allyn T Londregan
Alan M Mathiowetz
David W Piotrowski
Roger B Ruggeri
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20240584A1 publication Critical patent/PE20240584A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)

Abstract

Referido a un compuesto de formula I, o una sal farmaceuticamente aceptable del mismo, en donde R es F, Cl, o -CN; p es 0, o 1; el anillo A es fenilo o un heteroarilo de 6 miembros; m es 0, 1, 2, o 3; cada R1 se selecciona independientemente de halogeno, -CN, alquilo-C1-3, entre otros; R2 es H o alquilo-C1-3, en donde el alquilo se sustituye con 0 a 1 OH; cada R3 es independientemente F, -OH, -CN, alquilo-C1-3; entre otros; q es 0, 1, o 2; X-L es N-CH2, CHCH2, o ciclopropilo; Y es CH o N; R4 es alquilo-C1-3, alquileno-C0-3-cicloalquilo C3-6, o -alquileno C1-3-R6, en donde dicho alquilo puede sustituirse como lo permita la valencia con 0 a 3 sustituyentes; Z1, Z2 y Z3 son cada uno -CRz, o uno de Z1, Z2 y Z3 es N y los otros dos son -CRz; y cada Rz es independientemente H, F, Cl, o -CH3. Un compuesto seleccionado es acido 2-({4-[2-(4-cloro-2-fluorofenil)-2-metil-1,3-benzodioxol-4-il]piperidin-1-il}metil)-3-(1,3-oxazol-2-ilmetil)-3H-imidazo[4,5-b]piridin-5-carboxilico. Estos compuestos son agonistas del receptor de GLP-1. Tambien se refiere a procesos para elaborar dicho compuesto, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades cardiometabolicas y asociadas.
PE2023003553A 2018-06-13 2019-06-11 Agonistas del receptor de glp-1 y usos de los mismos PE20240584A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862684696P 2018-06-13 2018-06-13
US201962846944P 2019-05-13 2019-05-13
US201962851206P 2019-05-22 2019-05-22
PCT/IB2019/054867 WO2019239319A1 (en) 2018-06-13 2019-06-11 Glp-1 receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
PE20240584A1 true PE20240584A1 (es) 2024-03-21

Family

ID=67003576

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020001993A PE20211601A1 (es) 2018-06-13 2019-06-11 Agonistas del receptor de glp-1 y usos de los mismos
PE2023003553A PE20240584A1 (es) 2018-06-13 2019-06-11 Agonistas del receptor de glp-1 y usos de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2020001993A PE20211601A1 (es) 2018-06-13 2019-06-11 Agonistas del receptor de glp-1 y usos de los mismos

Country Status (40)

Country Link
US (6) US10934279B2 (es)
EP (2) EP4219487B9 (es)
JP (1) JP6916968B1 (es)
KR (1) KR102542199B1 (es)
CN (4) CN119462621A (es)
AU (1) AU2019285491B2 (es)
BR (1) BR112020024470A2 (es)
CA (1) CA3045644C (es)
CL (1) CL2020003222A1 (es)
CO (1) CO2020015305A2 (es)
CR (1) CR20200612A (es)
CU (1) CU20200099A7 (es)
CY (1) CY1126097T1 (es)
DK (2) DK3806955T3 (es)
EC (1) ECSP20078651A (es)
ES (2) ES2949954T3 (es)
FI (2) FI3806955T3 (es)
GE (1) GEP20237453B (es)
HR (2) HRP20250099T1 (es)
HU (2) HUE063074T2 (es)
IL (1) IL279300B2 (es)
LT (2) LT4219487T (es)
MA (1) MA64510B1 (es)
MD (2) MD4219487T3 (es)
MX (1) MX389121B (es)
MY (1) MY199157A (es)
NI (1) NI202000091A (es)
NZ (1) NZ770240A (es)
PE (2) PE20211601A1 (es)
PH (1) PH12020552069A1 (es)
PL (2) PL4219487T3 (es)
PT (2) PT4219487T (es)
RS (2) RS66418B9 (es)
SG (1) SG11202011465QA (es)
SI (2) SI4219487T1 (es)
TW (1) TWI707683B (es)
UA (1) UA124371C2 (es)
UY (1) UY38261A (es)
WO (1) WO2019239319A1 (es)
ZA (1) ZA202007572B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
PT3806855T (pt) 2018-06-15 2023-05-03 Pfizer Agonistas dos receptores de glp-1 e suas utilizações
AU2019382642B2 (en) * 2018-11-22 2025-05-29 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
BR112022007627A2 (pt) 2019-10-25 2022-07-12 Gilead Sciences Inc Compostos moduladores do glp-1r
TWI809334B (zh) * 2019-12-10 2023-07-21 美商輝瑞股份有限公司 ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
HUE067201T2 (hu) 2019-12-10 2024-10-28 Lilly Co Eli Eljárás és intermedier oxetan-2-il-metánamin elõállítására
CN115335374B (zh) * 2020-01-29 2025-05-27 吉利德科学公司 Glp-1r调节化合物
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
TW202144340A (zh) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN113493447B (zh) * 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
EP4143183B1 (en) * 2020-04-29 2025-10-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2021254470A1 (zh) * 2020-06-19 2021-12-23 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CR20230066A (es) 2020-08-06 2023-05-29 Gasherbrum Bio Inc Agonistas del glp-1 heterocíclicos
TW202214622A (zh) * 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
JP2023538949A (ja) * 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2023539584A (ja) 2020-09-01 2023-09-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
WO2022068772A1 (zh) * 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
JP2023546055A (ja) * 2020-10-13 2023-11-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN114478694A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效mc4r激动剂
US11851419B2 (en) * 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
US20240246959A1 (en) 2020-11-27 2024-07-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and medical use thereof
CN114591308B (zh) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
US12065434B2 (en) 2020-12-15 2024-08-20 Pfizer Inc. Metabolites of GLP1R agonists
US20220193063A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Metabolites of glp1r agonists
US20230089073A1 (en) 2021-01-28 2023-03-23 Carmot Therapeutics, Inc. Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CA3215916A1 (en) * 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
AU2022263410B2 (en) 2021-04-21 2024-08-01 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用
JP2024516291A (ja) * 2021-05-03 2024-04-12 カーモット セラピューティクス インコーポレイテッド ベンゾイミダゾイルｇｌｐ－１受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN117715906A (zh) * 2021-07-21 2024-03-15 和博医药有限公司 胰高血糖素样肽-1受体调节剂及其用途
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
WO2023011539A1 (zh) * 2021-08-04 2023-02-09 上海翰森生物医药科技有限公司 环烯类衍生物调节剂、其制备方法和应用
WO2023025201A1 (zh) * 2021-08-24 2023-03-02 南京明德新药研发有限公司 咪唑并环类化合物及其应用
CN118948849A (zh) 2021-09-08 2024-11-15 盐野义制药株式会社 用于预防和治疗与抗肥胖作用有关的疾病的药物
HRP20251161T1 (hr) 2021-09-27 2025-11-21 Terns Pharmaceuticals, Inc. Benzimidazol karboksilne kisele kao agonisti glp-1r
US20240417393A1 (en) * 2021-10-05 2024-12-19 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
US20250115612A1 (en) 2021-10-05 2025-04-10 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) * 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
CN115991685B (zh) 2021-10-20 2025-03-04 韶远科技（上海)有限公司 一种氧杂环丁烷-2-甲胺的制备方法
TWI843243B (zh) * 2021-10-22 2024-05-21 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
TW202334129A (zh) 2021-10-25 2023-09-01 美商拓臻製藥公司 作為ｇｌｐ—１ｒ促效劑的化合物
JPWO2023106310A1 (es) * 2021-12-07 2023-06-15
CN113974618B (zh) * 2021-12-12 2022-09-13 广西澍源智能科技有限公司 基于水峰血糖修正的无创血糖测试方法
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250049778A1 (en) * 2021-12-23 2025-02-13 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of glp-1 receptor agonist and preparation method therefor
CA3241670A1 (en) * 2021-12-23 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
CN116354945B (zh) * 2021-12-27 2024-08-30 长春金赛药业有限责任公司 一种稠合咪唑羧酸类化合物及其制备方法和应用
JP2025506473A (ja) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
JP2025506474A (ja) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
EP4476212A1 (en) 2022-02-10 2024-12-18 Novartis AG 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023164050A1 (en) 2022-02-23 2023-08-31 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CA3253533A1 (en) * 2022-02-28 2023-08-31 Ascletis Bioscience Co Ltd GLP-1R MODULATOR COMPOUNDS
EP4491625A1 (en) * 2022-03-08 2025-01-15 Guangzhou Unirise Pharmaceutical Co., Ltd. Benzo bicyclic compound, and preparation method and application thereof
WO2023228023A1 (en) 2022-05-23 2023-11-30 Pfizer Inc. Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
KR20250047817A (ko) * 2022-09-06 2025-04-04 민드랭크 테라퓨틱스 (수저우) 뉴 드러그 리서치 앤 디벨롭먼트 컴퍼니, 리미티드 Glp-1r 작용제 화합물의 결정다형체 및 이의 제조 방법과 용도
JPWO2024063143A1 (es) * 2022-09-22 2024-03-28
KR20250105662A (ko) 2022-11-11 2025-07-08 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드 1 수용체 효능제
EP4619098A1 (en) 2022-11-16 2025-09-24 Eli Lilly and Company Glucagon-like peptide 1 receptor agonists
CN115785066B (zh) 2022-12-08 2024-05-31 广东工业大学 曲格列汀晶型f及其制备方法
EP4650353A1 (en) 2023-01-13 2025-11-19 Shanghai Institute of Materia Medica, Chinese Academy of Sciences 4-alkoxy benzimidazole-6-carboxylic acid derivative serving as glp-1 receptor agonist
WO2024160271A1 (zh) * 2023-02-02 2024-08-08 江苏豪森药业集团有限公司 一种环烯类化合物的盐、晶型及其制备方法和应用
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法
WO2024214038A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
CN118812522A (zh) * 2023-04-21 2024-10-22 苏州闻泰医药科技有限公司 一种glp-1r受体激动剂化合物盐、其晶型、其制备方法和应用
AR133241A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
TW202521528A (zh) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 化合物、組合物及方法
USD1011080S1 (en) 2023-07-28 2024-01-16 Voilasophy, Llc. Yoga storage rack
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025140533A1 (en) * 2023-12-27 2025-07-03 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
WO2025140532A1 (en) * 2023-12-27 2025-07-03 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
WO2025158275A1 (en) * 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025163561A1 (en) 2024-02-01 2025-08-07 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
US20250326741A1 (en) 2024-04-22 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025224648A1 (en) 2024-04-26 2025-10-30 Pfizer Inc. Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994021615A1 (en) 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Benzimidazole derivatives
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
JP2005532991A (ja) * 2002-01-10 2005-11-04 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ
BR0313041A (pt) 2002-07-29 2005-06-21 Hoffmann La Roche Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US20090227493A1 (en) 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
ATE473004T1 (de) 2006-04-14 2010-07-15 Merck Sharp & Dohme Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2010028981A1 (en) 2008-09-11 2010-03-18 F. Hoffmann-La Roche Ag New benzimidazole derivatives
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102378574B (zh) * 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
DK2368890T3 (da) 2009-06-11 2013-07-22 Abbvie Bahamas Ltd Hepatitis C-virusinhibitorer
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
CN102946882B (zh) 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
WO2011097491A1 (en) 2010-02-04 2011-08-11 Glaxosmithkline Llc Benzimidazole antiviral agents
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
EP2802571A1 (en) 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
PH12017501029B1 (en) 2014-12-24 2022-04-27 Lg Chemical Ltd Biaryl derivative as gpr120 agonist
WO2016107603A1 (zh) 2015-01-01 2016-07-07 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3397631B1 (en) 2015-12-29 2021-04-07 Pfizer Inc Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
AU2017374860B2 (en) * 2016-12-16 2021-09-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN117222631A (zh) 2021-03-24 2023-12-12 诚益生物(美国)公司 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法
WO2022216094A1 (ko) 2021-04-08 2022-10-13 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
CN112533674A (zh) 2021-03-19
ES3012643T3 (en) 2025-04-09
FI3806955T3 (fi) 2023-07-27
MA64510B1 (fr) 2025-03-28
CY1126097T1 (el) 2023-11-15
PT3806955T (pt) 2023-07-20
US10934279B2 (en) 2021-03-02
ES2949954T3 (es) 2023-10-04
IL279300A (en) 2021-01-31
MY199157A (en) 2023-10-18
EP4219487B9 (en) 2025-03-26
CR20200612A (es) 2021-01-20
EP3806955B1 (en) 2023-05-31
CA3045644A1 (en) 2019-12-13
US20210163455A1 (en) 2021-06-03
MD4219487T2 (ro) 2025-04-30
MD3806955T3 (ro) 2024-01-31
NZ770240A (en) 2023-07-28
UA124371C2 (uk) 2021-09-01
US10683281B2 (en) 2020-06-16
AU2019285491A1 (en) 2020-12-17
MX389121B (es) 2025-03-20
DK3806955T3 (da) 2023-06-26
PL4219487T3 (pl) 2025-03-31
HRP20230631T1 (hr) 2023-09-29
EP4219487A1 (en) 2023-08-02
LT4219487T (lt) 2025-01-27
EP3806955A1 (en) 2021-04-21
ES2949954T9 (es) 2023-11-23
GEP20237453B (en) 2023-01-10
CN119431342A (zh) 2025-02-14
ZA202007572B (en) 2023-10-25
US20190382388A1 (en) 2019-12-19
HUE070423T2 (hu) 2025-06-28
MD4219487T3 (ro) 2025-05-31
MX2020013625A (es) 2022-01-04
IL279300B2 (en) 2023-11-01
LT3806955T (lt) 2023-07-10
CU20200099A7 (es) 2021-08-06
CN119462621A (zh) 2025-02-18
IL279300B1 (en) 2023-07-01
US20240059679A1 (en) 2024-02-22
HRP20250099T1 (hr) 2025-03-28
AU2019285491B2 (en) 2021-11-11
CL2020003222A1 (es) 2021-04-30
CO2020015305A2 (es) 2021-03-08
SI4219487T1 (sl) 2025-07-31
US20250340544A1 (en) 2025-11-06
KR102542199B1 (ko) 2023-06-13
JP2021521265A (ja) 2021-08-26
CA3045644C (en) 2024-01-16
PT4219487T (pt) 2025-02-18
JP6916968B1 (ja) 2021-08-11
US20190382384A1 (en) 2019-12-19
CN119462622A (zh) 2025-02-18
EP3806955B9 (en) 2023-08-23
EP4219487B1 (en) 2024-12-18
RS64323B1 (sr) 2023-08-31
DK4219487T5 (da) 2025-05-19
UY38261A (es) 2020-01-31
TWI707683B (zh) 2020-10-21
PL3806955T3 (pl) 2023-09-04
RS66418B1 (sr) 2025-02-28
RU2769715C1 (ru) 2022-04-05
US10676465B2 (en) 2020-06-09
ECSP20078651A (es) 2021-01-29
HUE063074T2 (hu) 2023-12-28
TW202015679A (zh) 2020-05-01
CN112533674B (zh) 2024-11-15
SG11202011465QA (en) 2020-12-30
KR20210019529A (ko) 2021-02-22
US12378230B2 (en) 2025-08-05
WO2019239319A1 (en) 2019-12-19
RS66418B9 (sr) 2025-05-30
SI3806955T1 (sl) 2023-08-31
RS64323B9 (en) 2023-11-30
NI202000091A (es) 2021-03-23
BR112020024470A2 (pt) 2021-03-02
PH12020552069A1 (en) 2021-05-31
FI4219487T3 (fi) 2025-02-24
PE20211601A1 (es) 2021-08-18
DK4219487T3 (da) 2025-02-03
US20190382387A1 (en) 2019-12-19
MD3806955T2 (ro) 2023-09-30

Similar Documents

Publication Publication Date Title
PE20240584A1 (es) Agonistas del receptor de glp-1 y usos de los mismos
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20191532A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
PE20211703A1 (es) Compuesto derivado heterotriciclico novedoso y uso del mismo
PE20211089A1 (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
PE20190475A1 (es) Inhibidores de cdk2/4/6
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR055630A1 (es) Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias.
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
AR076264A1 (es) Triazolopiridinas sustituidas y analogos de estas
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20190437A1 (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
AR112264A1 (es) Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
AR051753A1 (es) Metodos para preparar compuestos de indazol
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
CL2022000032A1 (es) Derivados de imidazo[4,5-c]piridina como agonistas de los receptores tipo toll
AR076714A1 (es) Agonistas del receptor de glucocorticoides
CR20170372A (es) Compuestos de benzoxaborol y usos de los mismos
PE20250118A1 (es) Inhibidores de mutacion de her2